03:43 PM EDT, 08/27/2025 (MT Newswires) -- Novavax ( NVAX ) said the US Food and Drug Administration approved its Nuvaxovid 2025-2026 COVID-19 vaccine for adults 65 and older, as well as individuals aged 12 to 64 with underlying conditions that increase the risk of severe disease.

Novavax ( NVAX ) said Wednesday it plans to work with its partner Sanofi ( SNY ) to offer the protein-based, non-mRNA COVID-19 vaccine available to eligible individuals this autumn.

Sanofi ( SNY ) is leading commercialization efforts for Nuvaxovid, while Novavax ( NVAX ) is eligible to receive tiered royalties from vaccine sales.

Shares of Novavax ( NVAX ) rose 1.9% in Wednesday trading, and Sanofi ( SNY ) fell 0.1%.

Price: 7.65, Change: +0.15, Percent Change: +1.93